Affiliated Institutions
Related Publications
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels ...
Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms
Abstract Purpose: In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells. Experimental Design: Using a panel of fo...
Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment
Abstract Purpose: Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide. Recently...
Coded M-DPSK with built-in time diversity for fading channels
Good coded modulation for fading channels requires built-in time diversity. Under a constraint on the interleaving delay, the authors construct and compare three categories of c...
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma mult...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
0
OpenAlex
0
Influential
0
CrossRef
Cite This
Smita Dey,
Sakshi Priya,
Gautam Singhvi
et al.
(2025).
Lipid Armor Loaded with Doxylamine and Gemfibrozil for Glioblastoma Therapy: Particle Engineering and Multidimensional Two-Dimensional/Three-Dimensional Antitumor Efficacy.
ACS Omega
.
https://doi.org/10.1021/acsomega.5c08873
Identifiers
- DOI
- 10.1021/acsomega.5c08873